Renal Division, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Trends Endocrinol Metab. 2021 May;32(5):261-263. doi: 10.1016/j.tem.2021.02.002. Epub 2021 Feb 23.
Hemodynamic alterations, metabolic dysfunction, inflammation, and fibrosis are the main drivers of diabetic kidney disease (DKD) progression. Targeting inflammation and fibrosis as a driver, the FIDELIO-DKD (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes) trial reported by Bakris et al. provides evidence of a new therapeutic class for treating DKD.
血流动力学改变、代谢功能障碍、炎症和纤维化是糖尿病肾病（DKD）进展的主要驱动因素。Bakris 等人报告的 FIDELIO-DKD（非奈利酮在 2 型糖尿病患者中的慢性肾脏病结局的影响）试验以炎症和纤维化作为驱动因素，为治疗 DKD 的新治疗类别提供了证据。
